In the specialized field of biochemical research, the exploration of synthetic sequences designed to replicate the biological activity of apolipoproteins has opened new avenues for understanding lipid metabolism. One such molecule that has garnered significant attention in the scientific literature is the ATI 5261 peptide. As an enthusiast of peptide chemistry and structural biology, I have spent considerable time reviewing the technical specifications and the unique properties that define this specific 26-mer construct.
Structural Characterization and Design
The ATI-5261 is a 26-mer peptide derived from th by S Nouri · 2025 · Cited by 1 — Here, we designed two novel apoA-I mimetic peptides (22A-F and 22A-P-18A) by modifying the sequence of the well-studied apoA-I mimetic peptide e carboxyl-terminal domain of human apolipoprotein E (apoE). By meticulously mimicking the amphipathic alpha-helical structure found in native proteins, this molecule demonstrates a high degree of structural effi Common pathways in cardiovascular disease and cancer ciency. Researchers often note that ATI-5261 is a novel, single-helix peptide characterized by its high aqueous solubility, which is a significant advantage when compared to more hydrophobic sequences.
From a structural standpoint, the peptide (ATI-5261) is engineered to facilitate interaction with lipid environments. Its ability to maintain a stable alpha-helical configuration allows it to function effectively in complex biological models. This design principle is shared with other ApoA-I mimetic peptide variants, which aim to replicate the functional capacity of high-density lipoprotein components.
Functional Observations in Research
The primary interest in this compound stems from its role in lipid transport dynamics. Studies have consistently demonstrated that ATI-5261 possesses potent HDL mimetic peptide ATI-5261 forms an oligomeric assembly cholesterol efflux activity, which is a critical metric for evaluating the efficacy of synthetic apolipoprotein mimetics.
In controlled laboratory environments, the molecule has shown remarkable performance. For instance, data indicates that it greatly reduces established atherosclerosis in hyperlipidemic mice, providing a foundational model for observing how these structures interact with systemic lipid markers. Furthermore, investigations involving ATI-5261 treatment in COMT−/− mice have shed light on the Common pathways in cardiovascular disease and cancer broader implications of its activity in vascu by A Hafiane · 2015 · Cited by 67 — CS-6253 is a modification of peptide ATI-5261 with a substitution of phenylalanine for leucine residues, and arginine for citrulline residues. For experiments, lar function.
Comparative Analysis: ATI-5261 and CS-6253
The evolution of these molecules often involves iterative improvements. It is well-documented that CS-6253 is a modification of peptide ATI-5261; this was achieved through specific amino acid substitutions, such as r by GD Wool · 2009 · Cited by 61 — Administration of biotinylated peptides to mice demonstrates that b4F does not associate with lipoproteins smaller than LDL in vivo, though it does associate eplacing leucine with phenylalanine and citrulline with arginine, to further optimize its interaction with cellular transporters like ABCA1.
When evaluating two novel (26-AA) apolipoprotein (apo) mimetic peptides ATI-5261 and its successor side-by-side, it becomes clear that the original design served as a vital scaffold for future research. Whether one is looking at the peptide ATI series or the broader category of peptides designed for lipid research, the foundational work established by the 5261 sequence remains highly relevant.
Scientific Context and Use
It is important to em This peptide (ATI-5261) greatly reduces established atherosclerosis in hyperlipidemic mice fed high-fat western-diet, similar to HDL-like particles (i.e. ETC- phasize that the literature often refers to AT1-5261 (a common variation in nomenclature) as a tool for studying cellular pathways. As someone who follows the development of these synthetic chains, I find the precision of their design—specifically the focus on the Apo A1 mimetic peptide functionality—to be a testament to the advancements in modern biochemistry.
These compounds are strictly for research purposes. Their role in the laboratory is to serve as models for investigating the intricate mechanisms of lipid efflux and the structural requirements of helical proteins. By maintaining a focus on the specific parameters—such as the 26-amino acid length and the unique helical orientation—researchers continue to refine our understanding of how these molecules mimic natural biological processes without the need for complex, native protein extraction.